Patent intelligence · EP
EP 2086964
BENZOYLAMINOHETEROCYCLYLVERBINDUNGEN, DIE SICH FÜR DIE BEHANDLUNG EINER DURCH GLK VERMITTELTEN KRANKHEIT EIGNEN
BENZOYLAMINOHETEROCYCLYLVERBINDUNGEN, DIE SICH FÜR DIE BEHANDLUNG EINER DURCH GLK VERMITTELTEN KRANKHEIT EIGNEN
Patent details — EP 2086964
- Jurisdiction
- EP
- Status
- granted
- Grant date
- Aug 12, 2009
- Expiration
- Aug 7, 2029
- Applicant
- ASTRAZENECA AB [SE]
- CPC classes
- A61K 31/ 444 A I, A61K 31/ 497 A I, A61K 31/ 553 A I, A61K 31/ 554 A I
Quick answer
EP 2086964 (BENZOYLAMINOHETEROCYCLYLVERBINDUNGEN, DIE SICH FÜR DIE BEHANDLUNG EINER DURCH GLK VERMITTELTEN KRANKHEIT EIGNEN) is held by ASTRAZENECA AB [SE]. Status: granted. Granted Aug 12, 2009. Expires Aug 7, 2029 (3 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- ASTRAZENECA AB [SE]
- Grant date
- Expiration
- Claims
- —
- CPC classes
- A61K 31/ 444 A I, A61K 31/ 497 A I, A61K 31/ 553 A I, A61K 31/ 554 A I, A61K 31/ 4155 A I, A61K 31/ 5355 A I
More from ASTRAZENECA AB [SE]
Related pharmaceutical patents in our USPTO index.
-
IL 240179
Use of a monoclonal, chimeric, human antibody that binds il-5r in the manufacture of a medicament for reducing the numbers of blood basophils in a human subject
granted -
ZA 201308176
THERAPEUTIC TREATMENT
granted -
SI 2158199
PIPERIDINE COMPOUNDS AND USES THEREOF
granted -
US 2010280048
Some 2-pyrazinone derivatives and their use as inhibitors of neutrophile elastase
granted -
DO P2009000148
DERIVADOS DE ESTER Y AMIDA DE INDAZOLILO PARA EL TRATAMIENTO DE ENFERMEDADES MEDIADAS POR UN RECEPTOR DE GLUCOCORTICOIDES
granted -
EP 2079730
MGLUR5-MODULATOREN
granted -
EP 2064340
VERFAHREN ZUR BEWERTUNG VON PATIENTEN BEI DER BEHANDLUNG MIT AUF RET-REZEPTOR-TYROSINKINASE ABZIELENDEN ARZNEISTOFFEN
granted
Frequently asked questions
What is US patent 2086964?
EP 2086964 (BENZOYLAMINOHETEROCYCLYLVERBINDUNGEN, DIE SICH FÜR DIE BEHANDLUNG EINER DURCH GLK VERMITTELTEN KRANKHEIT EIGNEN) is held by ASTRAZENECA AB [SE]. Status: granted. Granted Aug 12, 2009. Expires Aug 7, 2029 (3 years remaining) — relevant for patent-cliff and LOE planning.
Who owns EP 2086964?
ASTRAZENECA AB [SE] is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 25 pharmaceutical patents for this assignee.
When does EP 2086964 expire?
Our index shows an expiration date of Aug 7, 2029 (3 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.